Cormedix Inc CRMD

$7.85 -0.25 (-3.09%)

Valuation

Market cap
611,860,000
Revenue TTM
$311,710,000
Net income TTM
$163,060,000
PE ratio
4.26
Forward PE
15.00
Profit margin
52.31%
Debt to equity
0.00

Trading

Volume
894,500
Avg volume
1,076,022
Day's range
$7.79 – $8.11
Shares out
77,944,000
Stochastic %K
69%
Beta
1.40
Analysts
Strong Sell
Price target
$14.25

Price

Company profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company,...

Show more

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
908 517 9500
Website
https://cormedix.com
Address
389 Interpace Pkwy, Suite 450, Parsippany, United States

Latest news

Stocktwits

TSLA_S3XY Oct 25, 9:23 PM
$CRMD If you want a chat with CEO Joe show up to his son's football game on 10/30 (Holmdel) https://x.com/holmdel_fb2026/status/2114335200888947092?s=46
1 replies
wolfofwestloop Oct 25, 6:22 PM
$CRMD You know what this means!!! IYKYK
2 replies
Noname2022 Oct 25, 6:18 PM
$CRMD What could TPN pricing look like per vial? A pediatric intestinal-failure model estimated 40% fewer CLABSIs with ethanol locks—cost-saving at $63/day and cost-effective at $68/day. At an assumed 1 vial/day for NutriGuard, that puts a historical $60–$70/vial benchmark into perspective. Not DefenCath data or a price forecast, but useful context for the TPN opportunity. These are 2020 dollars. https://pubmed.ncbi.nlm.nih.gov/33908050/
1 replies
Noname2022 Oct 25, 5:31 PM
$CRMD $AKBA $FMS $DVA https://www.linkedin.com/posts/vivek-rathod-26396418_healthcare-story-who-really-runs-us-healthcare-share-7519700318020849664-qhbH/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7519700319249903617&highlightedUpdateType=SOCIAL_SHARE&origin=SOCIAL_SHARE&utm_source=share&utm_medium=member_ios&rcm=ACoAAAMWaIkBvm5PdlRwNiuTak_hl-r7IlDXarI
0 replies
Noname2022 Oct 25, 3:48 PM
$CRMD US Renal Care’s ASN operational poster (TH-PO1286), March 2025–February 2026: Of 18,151 CVC patients: • 7,417 (40.9%) received DefenCath during the year • 10,734 (59.1%) never received DefenCath Looking at actual treatment exposure: • DefenCath: 32.5% • Heparin: 67.5% The poster notes Medicare FFS patients predominated among DefenCath users. Takeaway: These figures align closely with our modeled ~34% FFS payer mix, suggesting strong FFS adoption. Medicare Advantage reimbursement remains a critical opportunity for expanding utilization. https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4588541
1 replies
Noname2022 Oct 25, 3:18 PM
$CRMD Fresenius ASN poster: 8,147 DefenCath vs. 10,231 ClearGuard patients (Aug–Sep 2025). Applying my CMS CVC model, assuming DefenCath users were Medicare FFS: • Long-term (≥90 days): 7,322 patients → ~78% modeled FFS penetration • Short-term (<90 days): 825 patients → ~9% modeled penetration Estimated overall long-term CVC mix: DefenCath 26% | ClearGuard 31% | Not captured 43% Takeaway: DefenCath appears widely adopted among long-term Medicare FFS patients. Broader adoption looks increasingly constrained by reimbursement, making Medicare Advantage coverage a critical growth opportunity. ASN abstract: https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4558700
0 replies
Noname2022 Oct 25, 3:03 PM
$CRMD My model of the U.S. outpatient dialysis CVC market, using 2024 CMS data to estimate the number of patients actively using a CVC in an average month, broken down by dialysis operator and catheter duration. Insurance mix is a best estimate based on industry payer trends, not actual customer-specific data. This represents the potential market, not DefenCath penetration. *long term is 90 day or more; short term less than 90 days https://data.cms.gov/provider-data/dataset/23ew-n7w9
1 replies
Merlintrader Oct 25, 12:58 PM
$CRMD closed at $7.85, between the 50-day EMA ($7.72) and the 200-day ($8.47). Tested support sits at $7.09-$7.28 and resistance at $8.94-$9.13. Daily RSI 56. Interactive chart at JC Just Charts: https://justcharts.merlintrader.com/#CRMD Not investment advice.
0 replies